Trial Profile

A randomized double-blinded pilot study of the efficacy and safety of dupilumab versus placebo in patients with Netherton syndrome

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 05 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary)
Indications Congenital ichthyosiform erythroderma
Focus Therapeutic Use
Acronyms NS-Dupi

Most Recent Events

02 Jun 2024 This trial has been completed in France (Global end date: 15 Nov 2022).
22 Aug 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
22 Aug 2023 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com